Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin alpha5beta1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs).
Purity:
>95.0%
CAS Number:
[]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
